Target intelligence / Profile preview

Bacterial DNA gyrase and DNA topoisomerase IV

Molecular classification
Enzyme, Topoisomerase, Type II topoisomerase
01

Overview

Bacterial DNA gyrase and DNA topoisomerase IV are two essential Type II topoisomerase enzymes found in bacteria. DNA gyrase primarily catalyzes the ATP-dependent introduction of negative supercoils into double-stranded DNA and is unique to bacteria. It plays a central role in resolving topological stress ahead of the replication fork during DNA replication, thus facilitating continued synthesis and genome maintenance[5][6]. DNA topoisomerase IV is responsible for decatenation, i.e., unlinking of interlinked (catenated) daughter chromosomes following DNA replication, and also helps relax positive supercoils[1][2][3][4]. Both enzymes function as heterotetramers: DNA gyrase is composed of GyrA and GyrB subunits, while topoisomerase IV consists of ParC and ParE subunits[1][4]. These enzymes are critical for bacterial viability and are prime targets for antibiotics, especially fluoroquinolones and related drugs, which trap enzyme-DNA complexes and induce lethal double-strand DNA breaks[3]. Resistance to these antibiotics frequently involves mutations in the genes encoding their subunits. Both enzymes are absent in higher eukaryotes (which have related topoisomerases but lack DNA gyrase specifically), making them attractive and selective antibacterial drug targets.

Other names
DNA gyraseGyraseDNA topoisomerase II (bacterial)Topoisomerase IVTopo IV
02

Mechanism of action

Inhibition of DNA supercoiling (gyrase) and decatenation (topoisomerase IV), leading to impaired DNA replication and segregation Stabilization of enzyme-DNA cleavage complexes, causing double-strand DNA breaks and cell death

03

Biological functions

DNA replicationDNA supercoiling controlDNA decatenation (unlinking of replicated chromosomes)Chromosome segregation
04

Disease associations

Infection (bacterial)
05

Safety considerations

Targeting bacterial DNA gyrase/topoisomerase IV can lead to rapid bacterial cell death, but resistance can develop quickly via target mutationsLimited specificity may affect commensal flora
06

Interacting drugs

Quinolones (e.g., ciprofloxacin, levofloxacin, norfloxacin)

2 more in the full profile.

07

Biomarkers

Mutations in the gyrA, gyrB (for gyrase), parC, parE (for topoisomerase IV) genes are used to detect resistance to quinolones in bacteria

Beyond the preview

Go deeper on Bacterial DNA gyrase and DNA topoisomerase IV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacterial DNA gyrase and DNA topoisomerase IV.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call